A distinct molecular mutational profile and its clinical impact in essential thrombocythemia and primary myelofibrosis patients

• Published in: BMC cancer 2020-03, Vol.20 (1), p.205-205, Article 205
• Main Authors: Zaidi, Uzma, Sufaida, Gul, Rashid, Munazza, Kaleem, Bushra, Maqsood, Sidra, Mukry, Samina Naz, Khan, Rifat Zubair Ahmed, Munzir, Saima, Borhany, Munira, Shamsi, Tahir Sultan
• Format: Article
• Language: English
• Subjects: Adult; Age; Aged; Aged, 80 and over; Anemia; BCR-ABL negative myeloproliferative neoplasm; Blood platelets; Bone marrow; Calreticulin - genetics; Care and treatment; Diagnosis; Disease Progression; DNA Mutational Analysis - methods; Early Diagnosis; Epigenetics; Essential thrombocythemia; FDA approval; Female; Genetic aspects; Humans; Janus Kinase 2 - genetics; Leukaemic free survival; Leukemia; Male; Medical prognosis; Medical research; Middle Aged; Mutation; Myelofibrosis; Overall survival; Pakistan; Patients; Primary myelofibrosis; Primary Myelofibrosis - diagnosis; Primary Myelofibrosis - genetics; Prospective Studies; Receptors, Thrombopoietin - genetics; Studies; Survival Analysis; Thrombocythemia, Essential - diagnosis; Thrombocythemia, Essential - genetics; Thrombosis; Tumors; Young Adult
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-020-6700-3

Classical MPNs including ET and PMF have a chronic course and potential for leukaemic transformation. Timely diagnosis is obligatory to ensure appropriate management and positive outcomes. The aim of this study was to determine the mutational profile, clinical characteristics and outcome of ET and PMF patients in Pakistani population. This was a prospective observational study conducted between 2012 and 2017 at NIBD. Patients were diagnosed and risk stratified according to international recommendations. Response to treatment was assessed by IWG criteria. Of the total 137 patients analysed, 75 were ET and 62 were PMF. JAK2 positivity was seen in 51 cases (37.2%), CALR in 41 cases (29.9%), while triple-negative in 17 (12.4%) cases. None of the patients in the present study were MPL positive. Overall survival for patients with ET and PMF was 92.5 and 86.0% respectively and leukaemia free survival was 100 and 91.6% respectively, at a median follow-up of 12 months. Leukaemic transformation occurred in 6.5% of MF patients; among them, JAK2 mutation was frequently found. Molecular mutations did not influence the OS in ET whereas in PMF, OS was shortest in the triple-negative PMF group as compared to the JAK2 and CALR positive patient groups. This study shows a different spectrum of molecular mutations in ET and PMF patients in Pakistani population as compared to other Asian countries. Similarly, the risk of leukaemic transformation in ET and PMF is relatively lower in our population of patients. The factors responsible for these phenotypic and genotypic differences need to be analysed in large scale studies with longer follow-up of patients.